cAMP-Screen Direct™ Cyclic AMP Immunoassay System
cAMP-Screen Direct™ Cyclic AMP Immunoassay System
Applied Biosystems™

cAMP-Screen Direct™ Cyclic AMP Immunoassay System

The cAMP-Screen Direct™ 96-well Cyclic AMP Immunoassay System enables ultrasensitive determination of cyclic AMP (cAMP) levels in cell lysates. This자세히 알아보기
Have Questions?
보기 방식 변경buttonViewtableView
카탈로그 번호수량
4412186192 assays (2 x 96)
4412187960 assays
카탈로그 번호 4412186
제품 가격(KRW)
1,576,000
Online offer
Ends: 31-Dec-2025
1,853,000
할인액 277,000 (15%)
Each
카트에 추가하기
수량:
192 assays (2 x 96)
제품 가격(KRW)
1,576,000
Online offer
Ends: 31-Dec-2025
1,853,000
할인액 277,000 (15%)
Each
카트에 추가하기
The cAMP-Screen Direct™ 96-well Cyclic AMP Immunoassay System enables ultrasensitive determination of cyclic AMP (cAMP) levels in cell lysates. This competitive chemiluminescent immunoassay is formatted with maximum flexibility to permit either manual reagent additions or automated high-throughput processing. The cAMP assay utilizes the highly sensitive chemiluminescent CSPD™ Substrate with Sapphire-II™ Enhancer that is triggered by an enzyme conjugate composed of cAMP bound to alkaline phosphatase (cAMP-AP). The chemiluminescent substrate/enhancer formulation is a ready-to-use reagent that generates a sustained-glow light emission from 30 minutes after addition. This assay is mainly used in secondary screening and pre-clinical research, where sensitivity and no false positives are essential.

• The highest sensitivity of any commercially available cAMP assay
• Hours of read time with little or no degradation of the signal
• A simple protocol with cells grown directly on the assay plate
• Useful for a wide range of receptor activation studies

High Sensitivity and Hours of Steady Glow Time
This chemiluminescent assay is designed to provide the highest sensitivity of any commercially available cAMP assay. As few as 60 femtomoles of cAMP can be detected. The assay has a wide dynamic range, detecting from 0.06 to 6,000 picomoles of cAMP without the need for sample dilution or manipulations such as acetylation. This is especially helpful in cell-based assays when measuring Gs- or Gi-coupled agonist or antagonist stimulation and/or inhibition. Intra-assay precision for duplicate samples is typically 5% or less. Once the substrate/enhancer formulation reaches glow signal, the plate can be read for hours with little or no degradation of the signal. This is useful in screens where several plates are compared with each other. In addition, the assay exhibits exceptionally low cross-reactivity with other adenosine-containing or cyclic nucleotides.

For Receptor Activation Studies
The cAMP-Screen Direct™ system is designed for quantitation of cellular cAMP for functional assays of receptor activation. The assay has been used with established cell lines for functional measurements with endogenous receptors, cell lines with exogenously expressed ligand receptors on the cell surface, primary cell cultures, and tissues in response to treatment with the appropriate ligands. In addition it has been used for receptor characterization, orphan receptor ligand identification, and the characterization of novel chimeric receptors. The assay can be used for high-throughput screens for compounds that stimulate or interfere with these signal transduction pathways.

A Simple Protocol—No Lysate Transfer Required
The assay follows a simple protocol. Cells are seeded into plates, cultured, and treated with test compounds as desired. Cell lysates are prepared in either the presence or absence of culture media. Lysates are incubated with a cAMP-AP conjugate and an anti-cAMP antibody in a coated microplate; the resulting immune complexes are captured in the plate. In samples without cAMP, all of the cAMP-AP conjugate is captured on the coated surface, resulting in a high signal. In the presence of cAMP, the amount of cAMP-AP conjugate captured decreases as a result of competition for binding with unlabeled cAMP, causing a reduced signal; signal reduction is proportional to the amount of cAMP present in the cell lysate. After washing to remove unbound cAMP-AP, the chemiluminescent substrate is added, and the resulting glow signal is measured in a luminometer.

This cAMP-Screen Direct™ system has all of the same benefits as the cAMP-Screen™ system, but also eliminates the need to transfer cell lysates from a tissue culture plate to the precoated microplates because the cells can be grown directly in the microplates. This provides better assay precision with one less transfer step. Many different cell types have been grown successfully on the precoated microplates, which also have a clear bottom to allow monitoring of cells.

For Research Use Only. Not for human or animal therapeutic or diagnostic use.
For Research Use Only. Not for use in diagnostic procedures.
사양
어세이 민감성60 femtomoles cAMP
용도(장비)Microplate Reader
유전자 ID(Entrez)Non-Gene
유전자 기호Non-Gene
라벨 또는 염료AP
제품라인cAMP-Screen Direct
단백질군GPCR (G-Protein Coupled Receptors)
수량192 assays (2 x 96)
샘플 부피60 μL
타겟 키트 이름 지정Cyclic AMP
검출 방법Chemiluminescence
샘플 종류Cell Culture
Unit SizeEach
구성 및 보관
1 kit, store at 2°C to 8 °C

자주 묻는 질문(FAQ)

What chemiluminescent detection assays do you offer for determining cyclic AMP levels in cell lysates?

We offer the cAMP-Screen and cAMP Screen Direct Cyclic AMP Immunoassay Systems for detection of cyclic AMP levels in cell lysates, see the products linked below:

cAMP-Screen Direct Cyclic AMP Immunoassay System (Cat. Nos. 4412186, 4412187)

cAMP-Screen Cyclic AMP Immunoassay System (Cat. Nos. 4412182, 4412183)

Find additional tips, troubleshooting help, and resources within our Cell Analysis Support Center.

인용 및 참조 문헌 (20)

인용 및 참조 문헌
Abstract
Augmented axonal defects and synaptic degenerative changes in female GRK5 deficient mice.
Authors:Li L, Rasul I, Liu J, Zhao B, Tang R, Premont RT, Suo WZ
Journal:Brain Res Bull
PubMed ID:18955119
'Recent studies suggested that G protein-coupled receptor kinase 5 (GRK5) deficiency plays a significant role in early Alzheimer''s disease (AD) pathogenesis, and that the GRK5 knockout (GRK5KO) mouse displays an early Alzheimer-like cognitive deficit associated with increased hippocampal axonal defects and synaptic degenerative changes. Gender is known to play a ... More
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
Authors:Neumann S, Huang W, Eliseeva E, Titus S, Thomas CJ, Gershengorn MC
Journal:Endocrinology
PubMed ID:20427476
'Small molecule inverse agonists for the TSH receptor (TSHR) may be used as probes of the role of basal (or agonist-independent or constitutive) signaling and may have therapeutic potential as orally active drugs to inhibit basal signaling in patients with thyroid cancer and in some patients with hyperthyroidism. We describe ... More
A homogeneous enzyme fragment complementation-based beta-arrestin translocation assay for high-throughput screening of G-protein-coupled receptors.
Authors:Zhao X, Jones A, Olson KR, Peng K, Wehrman T, Park A, Mallari R, Nebalasca D, Young SW, Xiao SH
Journal:J Biomol Screen
PubMed ID:18660457
'G-protein-coupled receptors (GPCRs) represent one of the largest gene families in the human genome and have long been regarded as valuable targets for small-molecule drugs. The authors describe a new functional assay that directly monitors GPCR activation. It is based on the interaction between beta-arrestin and ligand-activated GPCRs and uses ... More
Tumor necrosis factor (TNF)-soluble high-affinity receptor complex as a TNF antagonist.
Authors:McKenna SD, Feger G, Kelton C, Yang M, Ardissone V, Cirillo R, Vitte PA, Jiang X, Campbell RK
Journal:J Pharmacol Exp Ther
PubMed ID:17495128
'A novel high-affinity inhibitor of tumor necrosis factor (TNF) is described, which is created by the fusion of the extracellular domains of TNF-binding protein 1 (TBP-1) to both the alpha and beta chains of an inactive version of the heterodimeric protein hormone, human chorionic gonadotropin. The resulting molecule, termed TNF-soluble ... More
Occupancy of both sites on the thyrotropin (TSH) receptor dimer is necessary for phosphoinositide signaling.
Authors:Allen MD, Neumann S, Gershengorn MC
Journal:FASEB J
PubMed ID:21705666
'The thyroid-stimulating hormone (TSH) receptor signals via G(s) to produce cAMP and via G(q/11) to produce inositol-1,4,5-trisphosphate, which is degraded to inositol monophosphate (IP1; phosphoinositide signaling). The potency of TSH for cAMP signaling is higher than for phosphoinositide signaling, and it was suggested that there are "spare receptors" for cAMP ... More